Abstract
Background The immune form of thrombotic thrombocytopenic purpura (iTTP) and the hemolytic and uremic syndrome (HUS) are two major forms of thrombotic microangiopathy (TMA). Their treatment has been recently greatly improved. In this new era, both the prevalence and predictors of cerebral lesions occurring during the acute phase of these severe conditions remain poorly known.
Aim The prevalence and predictors of cerebral lesions appearing during the acute phase of iTTP and shigatoxin-producing Escherichia coli-HUS or atypical HUS were evaluated in a prospective multicenter study.
Methods Univariate analysis was performed to report the main differences between patients with iTTP and those with HUS or between patients with acute cerebral lesions and the others. Multivariable logistic regression analysis was used to identify the potential predictors of these lesions.
Results Among 73 TMA cases (mean age 46.89 ± 15.99 years (range: 21-87 years) with iTTP (n = 57) or HUS (n= 16), one third presented with acute ischemic cerebral lesions on magnetic resonance imagery (MRI); two individuals also had hemorrhagic lesions. One in ten patients had acute ischemic lesions without any neurological symptom. The neurological manifestations did not differ between iTTP and HUS. In multivariable analysis, 3 factors predicted the occurrence of acute ischemic lesions on cerebral MRI: 1) the presence of old infarcts on cerebral MRI, 2) the level of blood pulse pressure, 3) the diagnosis of iTTP.
Conclusion Cerebral MRI is crucial to detect both symptomatic and covert ischemic lesions at the acute phase of iTTP and HUS and helps identify patients with old infarcts, at the highest risk of neurological worsening. The diagnosis of iTTP further increases the risk of ischemic lesions but also an increased level of blood pressure that may represent a potential target to further improve the therapeutic management of these conditions.
Key points
- One third of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) or the hemolytic uremic syndrome (HUS) present with acute ischemic cerebral lesions on magnetic resonance imagery (MRI);
- The cerebral manifestations on MRI did not differ between iTTP and HUS;
- The presence of old infarcts on cerebral MRI, the level of blood pulse pressure and a diagnosis of iTTP predict the occurrence of acute ischemic lesions on cerebral MRI.
Competing Interest Statement
E.M. declares having received lecture fees from Sanofi and Takeda; A.V. is member of the Clinical Advisory Board for Sanofi and Takeda; P.C. is member of the Clinical Advisory Board for Alexion, Sanofi and Takeda; H.C. is member of an Advisory Board of Biogen and Hovid. Y.B., F.P., Pa.P. and A.W. are members of the clinical advisory board for Sanofi. The other authors declared no conflict of interest.
Clinical Trial
NCT02134171
Funding Statement
This work was funded by a grant from the French Ministry of Health (Projet Hospitalier de Recherche Clinique 2012; AOM12259). This work was also supported by the National Plan for Rare Diseases of the French Ministry of Health (Direction Générale l’Offre de Soin (DGOS)).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Délégation-la Recherche Clinique d’Ile-de-France(DRCI), Hôpital Saint-Louis, Paris, France
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Data are available on reasonable request.
